发明申请
- 专利标题： NOVEL ANTI-FIBROBLAST ACTIVATION PROTEIN (FAP) ANTIBODIES AND USES DERIVED THEREOF
-
申请号： US15541998申请日： 2016-01-11
-
公开(公告)号： US20170369592A1公开(公告)日： 2017-12-28
- 发明人: Chad BROKOPP , Jan GRIMM , Benoit COMBALUZIER , Mareike GOERANSON , Christine LOHMANN , Simon HOERSTRUP , Roger NITSCH
- 申请人： Mabimmune Diagnostics AG , Neurimmune Holding AG , University of Zurich
- 申请人地址： CH Schlieren CH Schlieren CH Zurich
- 专利权人： Mabimmune Diagostics AG,Neurimmune Holding AG,University of Zurich
- 当前专利权人： Mabimmune Diagostics AG,Neurimmune Holding AG,University of Zurich
- 当前专利权人地址： CH Schlieren CH Schlieren CH Zurich
- 优先权： EP15150691.2 20150109
- 国际申请： PCT/EP2016/050380 WO 20160111
- 主分类号： C07K16/40
- IPC分类号： C07K16/40 ; G01N33/573 ; A61K47/68 ; C12N9/48 ; C07K16/28 ; G01N33/574
摘要：
Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
信息查询
